- Home
- FTS vs BIIB Comparison
FTS vs BIIB Comparison
Compare FTS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTS | BIIB |
|---|---|---|
| Founded | 1885 | 1978 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.5B | 29.9B |
| IPO Year | 2016 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FTS | BIIB |
|---|---|---|
| Price | $55.57 | $212.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 25 |
| Target Price | $67.00 | ★ $206.83 |
| AVG Volume (30 Days) | 643.4K | ★ 647.1K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.15 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $11.05 | N/A |
| Revenue Next Year | $5.32 | N/A |
| P/E Ratio | ★ $22.72 | $102.71 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $48.69 | $135.39 |
| 52 Week High | $59.40 | $225.80 |
Technical Indicators
Market Signals| Indicator | FTS | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 49.28 |
| Support Level | $54.73 | $184.50 |
| Resistance Level | $57.69 | $219.24 |
| Average True Range (ATR) | 0.82 | 5.41 |
| MACD | 0.07 | -0.39 |
| Stochastic Oscillator | 56.00 | 22.02 |
Price Performance
Historical ComparisonAbout FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).